Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not
B Ettinger, JT Citron, B Livermore, LI Dolman - The Journal of urology, 1988 - Elsevier
We examined the effectiveness of chlorthalidone or magnesium hydroxide in the prevention
of recurrent calcium oxalate kidney calculi. In a double-blind random allocation design daily
dosages of 25 or 50 mg. chlorthalidone, 650 or 1,300 mg. magnesium hydroxide, or an
identical placebo were administered. All groups showed significantly decreased calculous
events compared to the pretreatment rates. During the trial 56.1 per cent fewer calculi than
predicted developed in the placebo group (p less than 0.01), whereas the groups receiving …
of recurrent calcium oxalate kidney calculi. In a double-blind random allocation design daily
dosages of 25 or 50 mg. chlorthalidone, 650 or 1,300 mg. magnesium hydroxide, or an
identical placebo were administered. All groups showed significantly decreased calculous
events compared to the pretreatment rates. During the trial 56.1 per cent fewer calculi than
predicted developed in the placebo group (p less than 0.01), whereas the groups receiving …
